{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:37:33Z","timestamp":1791859053631,"version":"4.3.4"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabidiol (CBD) is approved for treatment of seizures associated with two forms of epilepsy that become apparent in infancy or early childhood. To consider an adult physiologically\u2010based pharmacokinetic (PBPK) model for pediatric scaling, we assessed in vitro\u2010derived cytochrome P450 (CYP) and uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase (UGT) enzyme contributions to CBD clearance in human. An i.v. PBPK model was constructed using CBD physicochemical properties and knowledge of disposition. The i.v. datasets were used for model building and evaluation. Oral PBPK models for CBD administered in fasted and fed states were developed using single dose oral datasets and parameters optimized from the i.v. model and evaluated with multiple dose datasets. Relative contributions of CBD metabolizing enzymes were partitioned according to in vitro studies. Clinical drug\u2013drug interaction (DDI) studies were simulated using CBD fed state, itraconazole, fluconazole, and rifampicin PBPK models. Linear mixed effect modeling was used to estimate area under the concentration\u2010time curve from zero to infinity (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) perpetrator + CBD versus CBD alone. The i.v. and oral datasets used in model evaluation produced acceptable average fold error (AFE) of 1.28 and absolute AFE of 1.65. Relative contributions of drug\u2010metabolizing enzymes to CBD clearance were proposed from in vitro data: UGT1A7 4%, UGT1A9 16%, UGT2B7 10%, CYP3A4 38%, CYP2C19 21%, and CYP2C9 11%. The simulated DDI studies using the in vitro\u2010derived values produced AUC<jats:sub>0\u2013\u221e<\/jats:sub> treatment ratios comparable to observed: itraconazole 1.24 versus 1.07, fluconazole 1.45 versus 1.22, and rifampicin 0.49 versus 0.69. The constructed CBD PBPK models can predict adult exposures and have potential for use in pediatrics where exposure estimates are limited.<\/jats:p>","DOI":"10.1002\/psp4.12908","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:05:21Z","timestamp":1671606321000},"page":"320-332","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Verifying in vitro\u2010determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically\u2010based pharmacokinetic modeling"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-6376","authenticated-orcid":false,"given":"Cindy H. T.","family":"Yeung","sequence":"first","affiliation":[{"name":"School of Pharmacy University of Waterloo  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-2136","authenticated-orcid":false,"given":"Jessica L.","family":"Beers","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill  Chapel Hill California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klarissa D.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill  Chapel Hill California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Waterloo  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6NP00074F"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01365"},{"key":"e_1_2_10_4_1","volume-title":"Metabolism of Cannabinoids in Man","author":"Wall ME","year":"1976"},{"key":"e_1_2_10_5_1","unstructured":"Center for Drug Evaluation and Research.Clinical Pharmacology and Biopharmaceutics Review(s): Epidiolex.2017. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210365Orig1s000ClinPharmR.pdf. [Accessed March 31 2022]."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0578-5"},{"key":"e_1_2_10_7_1","unstructured":"Cannabidiol [Internet]. Available from:https:\/\/go.drugbank.com\/drugs\/DB09061. [Accessed October 8 2021]."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00741-5"},{"key":"e_1_2_10_9_1","unstructured":"European Medicines Agency. Assessment Report: Epidyolex.Committee for Medicinal Products for Human Use (CHMP).2019. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/epidyolex\u2010epar\u2010public\u2010assessment\u2010report_en.pdf. [Accessed March 31 2022]."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-236"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16674"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.05.018"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.026898"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000350"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259009046849"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9451-0"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20322"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20502"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9210-3"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2007.09.010"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20073"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2377"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9053-5"},{"key":"e_1_2_10_24_1","unstructured":"Open Systems Pharmacology \u2010 PBPK Model Library \u2010 Itraconazole [Internet].2020. Available from:https:\/\/github.com\/Open\u2010Systems\u2010Pharmacology\/OSP\u2010PBPK\u2010Model\u2010Library\/tree\/v9.1.1\/Itraconazole. [Accessed October 24 2021]."},{"key":"e_1_2_10_25_1","unstructured":"Open Systems Pharmacology \u2010 PBPK Model Library \u2010 Fluconazole [Internet].2021. Available from:https:\/\/github.com\/Open\u2010Systems\u2010Pharmacology\/Fluconazole\u2010Model. [Accessed October 13 2021]."},{"key":"e_1_2_10_26_1","unstructured":"Open Systems Pharmacology \u2010 PBPK Model Library \u2010 Rifampicin [Internet].2021. Available from:https:\/\/github.com\/Open\u2010Systems\u2010Pharmacology\/OSP\u2010PBPK\u2010Model\u2010Library\/tree\/master\/Rifampicin. [Accessed February 16 2022]."},{"key":"e_1_2_10_27_1","unstructured":"U.S. Food and Drug Administration.Drug Development and Drug Interactions: Table of Substrates Inhibitors and Inducers. 03\/10\/2020. Available from:https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/drug\u2010development\u2010and\u2010drug\u2010interactions\u2010table\u2010substrates\u2010inhibitors\u2010and\u2010inducers. [Accessed March 31 2022]."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199603000-00015"},{"key":"e_1_2_10_29_1","first-page":"414","article-title":"Warfarin\u2010fluconazole. I. Inhibition of the human cytochrome P450\u2010dependent metabolism of warfarin by fluconazole: in vitro studies","volume":"24","author":"Kunze KL","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2011.04.010"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.15.8719"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.123.369"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.452"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.21.357"},{"key":"e_1_2_10_35_1","unstructured":"Greenwich Biosciences Inc.EPIDIOLEX (Cannabidiol) Oral Solution Label; 6\/2018. Report No.: 4282447."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16419"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665"},{"issue":"1","key":"e_1_2_10_38_1","first-page":"S42","article-title":"Characterization of the ontogeny of hepatic UDP\u2010glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Bad\u00e9e J","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043752"},{"key":"e_1_2_10_40_1","first-page":"610","article-title":"Formation of (R)\u20108\u2010hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)\u2010mephenytoin hydroxylase, P4502C19","volume":"24","author":"Wienkers LC","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.291"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01054-17"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000823"},{"key":"e_1_2_10_44_1","volume-title":"Development of Liquid Chromatography\u2010Tandem Mass Spectrometry Methods of Cannabinoids For Pediatric Patient Samples","author":"Vuong S","year":"2020"},{"key":"e_1_2_10_45_1","unstructured":"Center for Drug Evaluation and Research. Non\u2010Clinical Review(s) Epidiolex2017. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210365Orig1s000PharmR.pdf. [Accessed March 31 2022]."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1412"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5AY01595B"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000073"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200130206"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00841-6"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.07.027"},{"key":"e_1_2_10_52_1","unstructured":"Center for Drug Evaluation and Research. Other Review(s): Sponsor's Submission GWEP1541.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210365Orig1s000OtherR.pdf. [Accessed March 31 2022]."},{"key":"e_1_2_10_53_1","unstructured":"7\u2010Hydroxycannabidiol [Internet]. PubChem.2022. Available from:https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/7\u2010Hydroxycannabidiol. [Accessed May 21 2022]."}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12908","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:03:45Z","timestamp":1694891025000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,8]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/psp4.12908"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12908","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,8]]},"assertion":[{"value":"2022-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}